Table 1.
Patients’ characteristics of training and validation cohort.
| Characteristic | Training cohort | External Validation cohort |
|---|---|---|
| Patient Number | 69 | 44 |
| Age (years) | ||
| Mean ± standard deviation | 61.1 ± 14.8 | 57.5 ± 15 |
| Sex (male/female) | 41/28 (59.4%/40.6%) | 26/18 (59.1%/40.9%) |
| Tumor type, n (%) | 69 (100%) | 44(100%) |
| Benign | 37 (53.6%) | 24 (38.6%) |
| Pleomorphic adenoma | 18 (26,1%) | 17 (38.6%) |
| Basal cell adenoma | 2 (2.9%) | - |
| Adenomyoepithelioma | 1 (1.5%) | - |
| Myoepithelial | 2 (2.9%) | - |
| Oncocytoma | 1 (1.5%) | - |
| Warthin tumor | 13 (18,8%) | 7 (15.9%) |
| Malignant | 32 (36.4%) | 20 (45.5%) |
| Mucoepidermoid carcinoma | 5 (7.2%) | 3 |
| Acinic cell carcinoma | 2 (2.9%) | 3 |
| Ductal carcinoma | 4 (5.8%) | 3 |
| Adenoidocystic carcinoma | 6 (8.7%) | 4 |
| Lymphoepithelial carcinoma | 3 (4.4%) | 7 others (3 high grade, 1 cystadenocarcinoma, 3 myoepithelial) |
| Carcinoma ex pleomorphic adenoma | 1 (1.5%) | |
| Squamous cell carcinoma | 1 (1.5%) | |
| Metastasis | 10 (14.5%) |